NUWE News & Events

Nuwellis announced that the U.S. Patent and Trademark Office, or USPTO, has issued a notice of allowance for a new patent covering its novel dual lumen midline catheter technology designed for use in ultrafiltration therapies. This catheter incorporates design elements to optimize blood flow dynamics during therapy. The technology includes separate withdrawal and infusion lumens with pressure-balancing features that help maintain stable flow and reduce complications associated with fluid removal procedures.

Nuwellis announces the return of three former team members: Liby Cielo, Principal Account Manager; Meredith Stein, Senior Clinical Education Specialist; and Scott Campbell, Area Vice President, Sales. "The addition of these returning team members reflects Nuwellis' continued focus on strengthening its commercial and clinical capabilities and supporting hospitals treating patients with complex cardiorenal conditions," the company said.

Nuwellis announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets. By establishing a focused territory, the company aims to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, including Aquadex therapy. "Expanding our presence in strategic hospital markets enables closer collaborations with clinicians as they evaluate and implement ultrafiltration therapy," said John Erb, CEO of Nuwellis. The addition of the South Texas territory reflects Nuwellis' continued focus on strengthening its commercial organization and supporting hospitals treating patients with complex cardiorenal conditions.

Nuwellis completed its acquisition of Rendiatech, an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense following its bankruptcy proceedings; the company purchased Rendiatech primarily to gain access to such assets. Rendiatech's technology enables automated, continuous renal monitoring with real-time data capture, replacing manual collection and intermittent readings.